The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Open accessAbstract
Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors.Methods Two neuroradiologists independently reviewed 2572 fluid-attenuated inversion recovery (FLAIR) MRI scans from 262 participants in two phase 2 studies of bapineuzumab and an open-label extension study. Readers were masked to the patient's treatment, APOE ɛ4 genotype, medical history, and demographics. Patients were included in risk analyses if they had no evidence of ARIA-E in their pre-treatment MRI, had received bapineuzumab, and had at least one MRI scan after treatment. We used Kaplan-Meier survival analysis to examine the distribution of incident ARIA-E from the start of bapineuzumab treatment and proportional hazards regression models to assess risk factors associated with ARIA.Findings 210 patients were included in the risk analyses. 36 patients (17%) developed ARIA-E during treatment with bapineuzumab; 15 of these ARIA-E cases (42%) had not been detected previously. 28 of these patients (78%) did not report associated symptoms. Adverse events, reported in eight symptomatic patients, included headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 of the patients with ARIA-E (47%), compared with seven of 177 (4%) patients without ARIA-E. 13 of the 15 patients in whom ARIA were detected in our study received additional treatment infusions while ARIA-E were present, without any associated symptoms. Occurrence of ARIA-E increased with bapineuzumab dose (hazard ratio [HR] 2·24 per 1 mg/kg increase in dose, 95% CI 1·40-3·62; p=0·0008) and presence of APOE ɛ4 alleles (HR 2·55 per allele, 95% CI 1·57-4·12; p=0·0001).Interpretation ARIA consist of a spectrum of imaging findings with variable clinical correlates, and some patients with ARIA-E remain asymptomatic even if treatment is continued. The increased risk of ARIA among APOE ɛ4 carriers, its association with high bapineuzumab dose, and its timecourse in relation to dosing suggest an association between ARIA and alterations in vascular amyloid burden.Funding Elan Corporation, Janssen Alzheimer Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The main adverse effects associated with administration of certain anti-Aβ mAbs during clinical trials were amyloid related imaging abnormalities (ARIA) identified on magnetic resonance imaging (MRI) scans.”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However one needs to be mindful that escalation of anti-Aβ mAbs dose in APOE ε4 allele carriers may trigger increased rate of vasculotropic adverse events associated with immunization [5, 8, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Some amyloid β antibodies triggered amyloid-related imaging abnormalities (ARIAs) in clinical trials and ARIAs tend to be more frequent in APOE4 carriers [28].”
From Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease (2017) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ApoE ε4 status has gained direct clinical relevance in the anti-amyloid era”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“ε4 carriers, particularly ε4 homozygotes, exhibit a substantially increased risk of amyloid-related imaging abnormalities (ARIA) during treatment with anti-amyloid monoclonal antibodies [2, 5, 8].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Pathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationPrevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study
Vernooij, M. W., van der Lugt, A., Ikram, M. A., Wielopolski, P. A., Niessen, W. J., Hofman, A., Krestin, G. P., & Breteler, M. M. B. (2008) · Neurology · doi:10.1212/01.wnl.0000307750.41970.d9 · Cited by 793
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationWeller, R. O., Subash, M., Preston, S., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 697
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gómez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 547
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Cited by
Sorted by citations
Items 101–200 of 506
Uekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00660-1 · Cited by 80
“ARIA is observed with MRI in cortical areas in up to 47% of patients receiving Aβ immunotherapy at the highest dose [86, 87].”
BackgroundInfluentialKetter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160216 · Cited by 81
Self-citationBiomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
Blennow, K., Hampel, H. J., & Zetterberg, H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.154 · Cited by 83
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180484 · Cited by 80
Graff‐Radford, J., Botha, H., Rabinstein, A. A., Gunter, J. L., Przybelski, S. A., Lesnick, T. G., Huston, J., Flemming, K. D., Preboske, G. M., Senjem, M. L., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006780 · Cited by 80
DiFrancesco, J. C., Longoni, M., & Piazza, F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00207 · Cited by 80
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
Castello, M. A., Jeppson, J. D., & Soriano, S. (2014) · BMC Neurology · doi:10.1186/s12883-014-0169-0 · Cited by 80
Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 79
Self-citationCarare, R. O., Aldea, R., Agarwal, N., Bacskai, B. J., Bechman, I., Boche, D., Bu, G., Bulters, D. O., Alt, C., Counts, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12053 · Cited by 77
Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease
Benedictus, M. R., Goos, J. D. C., Binnewijzend, M. A. A., Muller, M., Barkhof, F., Scheltens, P., Prins, N. D., & van der Flier, W. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.023 · Cited by 81
Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
Prins, N. D., & Scheltens, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt220 · Cited by 79
Zago, W., Schroeter, S., Guido, T., Khan, K., Seubert, P., Yednock, T., Schenk, D., Gregg, K. M., Games, D., Bard, F., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.010 · Cited by 75
Self-citationLa Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Cerebral amyloid angiopathy-related inflammation: current status and future implications
Wu, J., Yao, M., & Ni, J. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001427 · Cited by 74
Bouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 74
Bayesian latent time joint mixed effect models for multicohort longitudinal data
Li, D., Iddi, S., Thompson, W. K., Donohue, M., & Initiative, A. D. N. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217737566 · Cited by 81
Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
VandeVrede, L. A., Gibbs, D. M., KOESTLER, M. E., Joie, R. L., Ljubenkov, P. A., Provost, K., Soleimani‐Meigooni, D. N., Strom, A., Tsoy, E., Rabinovici, G. D., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12101 · Cited by 74
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74
Irwin, R. W., Solinsky, C. M., & Brinton, R. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00203 · Cited by 76
Button, E. B., Boyce, G. K., Wilkinson, A., Stukas, S. K., Hayat, A., Fan, J., Wadsworth, B. J., Robert, J., Martens, K. M., & Wellington, C. L. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0497-9 · Cited by 73
Sur, C., Kost, J. T., Scott, D., Adamczuk, K., Fox, N. C., Cummings, J. L., Tariot, P. N., Aisen, P. S. S., Vellas, B. J., Voss, T., et al. (2020) · Brain · doi:10.1093/brain/awaa332 · Cited by 71
Self-citationPenninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 71
Focal hemosiderin deposits and β‐amyloid load in the ADNI cohort
Kantarci, K., Gunter, J. L., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Petersen, R. C., Aisen, P. S. S., Jagust, W. J., Weiner, M. W., Jack, C. R., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.10.011 · Cited by 71
Bales, K. R., O’Neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., Wood, K. M., Volfson, D., Cirrito, J. R., Han, B.-H., et al. (2016) · Brain · doi:10.1093/brain/awv313 · Cited by 68
Cavedo, E., Lista, S., Khachaturian, Z., Aisen, P., Amouyel, P., Herholz, K., Jack Jr, C. R., Sperling, R., Cummings, J., Blennow, K., et al. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.32 · Cited by 67
Self-citationJackson, H. M., Soto, I., Graham, L. C., Carter, G. W., & Howell, G. R. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-831 · Cited by 66
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 69
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Carlson, C. D., Siemers, E., Hake, A. M., Case, M. G., Hayduk, R., Suhy, J., Oh, J., & Barakos, J. A. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.004 · Cited by 67
Self-citationSumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400348n · Cited by 65
Sepehry, A. A., Lang, D. J., Hsiung, G. R., & Rauscher, A. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4525 · Cited by 69
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
Frost, J. L., Liu, B., Rahfeld, J., Kleinschmidt, M., O’Nuallain, B., Le, K. X., Lues, I., Caldarone, B. J., Schilling, S., Demuth, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.021 · Cited by 64
Hattori, Y., Okamoto, Y., Maki, T., Yamamoto, Y., Oishi, N., Yamahara, K., Nagatsuka, K., Takahashi, R., Kalaria, R. N., Fukuyama, H., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006265 · Cited by 64
Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease
Berk, C., & Sabbagh, M. N. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0108-6 · Cited by 63
Self-citationCerebral amyloid angiopathy: diagnosis and potential therapies
Weber, S. A., Patel, R. K., & Lutsep, H. L. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1480938 · Cited by 63
Imaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Sebastien Ourselin, A., & Fox, N. C. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
Self-citationWalters, S., Contreras, A. G., Eissman, J. M., Mukherjee, S., Lee, M. L., Choi, S., Scollard, P., Trittschuh, E. H., Mez, J., Bush, W. S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2169 · Cited by 65
Salloway, S., Wojtowicz, J., Voyle, N., Lane, C., Klein, G., Lyons, M., Rossomanno, S., Mazzo, F., Bullain, S., Barkhof, F., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3937 · Cited by 62
Self-citationDo current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?
Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A. P., Perez, K. A., McLean, C., Villemagne, V. L., Parker, M. W., Barnham, K. J., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1290-2 · Cited by 60
An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion
Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., & Wattjes, M. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3475 · Cited by 60
Self-citationNew treatment strategies for Alzheimer's disease: is there a hope?
Aprahamian, I., Stella, F., & Forlenza, O. V. (2013) · Europe PMC (PubMed Central) · Cited by 59
Cerebral Amyloid Angiopathy Associated with Inflammation: Report of 3 Cases and Systematic Review
Caldas, A. C., Silva, C., Albuquerque, L., Pimentel, J., SILVA, V. Y. N. E. D., & Ferro, J. M. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.04.015 · Cited by 59
Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S. L., & Kupiec, J. W. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 61
Self-citationDeveloping therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
Carmona‐Iragui, M., Fernández‐Arcos, A., Alcolea, D. A., Piazza, F., Morenas‐Rodríguez, E., Antón‐Aguirre, S., Sala, I., Clarimón, J., Dols‐Icardo, O., Camacho, V., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150614 · Cited by 58
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 60
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 57
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund‐Carlsen, P. F., Neve, R. L., Alavi, A. A., Herrup, K., Perry, G. L., Robakis, N. K. R. K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230099 · Cited by 56
Nasr, S. H., Kouyoumdjian, H., Mallett, C. L., Ramadan, S., Zhu, D. C., Shapiro, E. M., & Huang, X. (2017) · Small · doi:10.1002/smll.201701828 · Cited by 55
Clinical considerations in early-onset cerebral amyloid angiopathy
Banerjee, G., Collinge, J., Fox, N. C., Lashley, T., Mead, S., Schott, J. M., Werring, D. J., & Ryan, N. S. (2023) · Brain · doi:10.1093/brain/awad193 · Cited by 54
Self-citationGrill, J. D., Zhou, Y. F., Elashoff, D. A., & Karlawish, J. H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.007 · Cited by 53
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease
Novak, G., Fox, N. C., Clegg, S., Nielsen, C. F., Einstein, S. G., Lü, Y., Tudor, I. C., Gregg, K. M., Di, J., Collins, P. V., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150448 · Cited by 54
Self-citationFeinberg, H., Saldanha, J. W., Diep, L., Goel, A. S., Widom, A., Veldman, G. M., Weis, W. I., Schenk, D., & Basi, G. S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt261 · Cited by 52
Liu, X., Zhang, L., Lü, S., Liu, D., Huang, Y., Zhu, J., Zhou, W.-W., Yu, X., & Liu, R. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00723-1 · Cited by 51
Retracted“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Chimeric antigen receptor macrophages target and resorb amyloid plaques
Kim, A. B., Xiao, Q., Yan, P., Pan, Q., Pandey, G., Grathwohl, S., Gonzales, E. R., Xu, I., Cho, Y., Haecker, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175015 · Cited by 50
Diffusion kurtosis imaging to detect amyloidosis in an APP/PS1 mouse model for Alzheimer's disease
Vanhoutte, G., Pereson, S., y Palacios, R. D., Guns, P., Asselbergh, B., Veraart, J., Sijbers, J., Verhoye, M., Broeckhoven, C. V., & der Linden, A. V. (2013) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24680 · Cited by 51
Carare, R. O., Teeling, J. L., Hawkes, C. A., Püntener, U., Weller, R. O., Nicoll, J. A. R., & Perry, V. H. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-48 · Cited by 51
Schroeder, S. K., Joly‐Amado, A., Gordon, M. N., & Morgan, D. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9637-6 · Cited by 51
Joseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wáng, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 48
Self-citationLathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P. (2016) · Brain · doi:10.1093/brain/aww036 · Cited by 49
A Rapidly Progressive Dementia
Charidimou, A., & Werring, D. J. (2015) · Springer eBooks · doi:10.1007/978-1-4471-6705-1_1 · Cited by 46
Meilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45
Self-citationSima, D. M., Phan, T. V., Eyndhoven, S. V., Vercruyssen, S., Magalhães, R. J. D. S., Liseune, A., Brys, A., Frenyo, P., Terzopoulos, V., Maes, C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.55800 · Cited by 46
Boncoraglio, G. B., Piazza, F., Savoiardo, M., Farina, L., DiFrancesco, J. C., Prioni, S., Tagliavini, F., Parati, E. A., & Giaccone, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142376 · Cited by 45
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 48
Patel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
Modulation of innate immunity of patients with Alzheimer's disease by omega‐3 fatty acids
Fiala, M., Kooij, G., Wagner, K. M., Hammock, B. D., & Pellegrini, M. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700065r · Cited by 45
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46
Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 46
Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production
Lovell, M. A., Abner, E. L., Kryscio, R. J., Xu, L., Fister, S. X., & Lynn, B. C. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/787805 · Cited by 47
Effect of active A β immunotherapy on neurons in human Alzheimer's disease
Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4491 · Cited by 44
Mead, S., Burnell, M., Lowe, J., Thompson, A. G. B., Lukić, A., Porter, M., Carswell, C. J., Kaski, D. N., Kenny, J., Mok, T. H., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4885 · Cited by 43
Vaccination strategies in tauopathies and synucleinopathies
Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 44
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R. A., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J. R., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 42
Self-citationGustafsson, S. S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund‐Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Chantran, Y., Capron, J., Alamowitch, S., & Aucouturier, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01534 · Cited by 42
Jeong, S. Y., Suh, C. H., Shim, W. H., Lim, J., Lee, J., & Kim, S. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201019 · Cited by 45
Pseudotumoral presentation of cerebral amyloid angiopathy–related inflammation
Ronsin, S., Deiana, G., Geraldo, A. F., Durand‐Dubief, F., Thomas, L., Formaglio, M., Desestret, V., Meyronet, D., Nighoghossian, N., Berthezène, Y., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002444 · Cited by 42
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Loomis, S. J., Miller, R., Castrillo‐Viguera, C., Umans, K., Cheng, W., O'Gorman, J. T., Hughes, R. A., Haeberlein, S. B., & Whelan, C. D. (2023) · Neurology · doi:10.1212/wnl.0000000000207919 · Cited by 41
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
Sprügel, M. I., Kuramatsu, J. B., Volbers, B., Gerner, S. T., Sembill, J. A., Madžar, D., Bobinger, T., Kölbl, K., Hoelter, P., Lücking, H., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008129 · Cited by 41
APOE Antibody Inhibits Aβ‐Associated Tau Seeding and Spreading in a Mouse Model
Gratuze, M., Jiang, H., Wang, C., Xiong, M., Bao, X., & Holtzman, D. M. (2022) · Annals of Neurology · doi:10.1002/ana.26351 · Cited by 41
Fujishima, M., Kawaguchi, A., Maikusa, N., Kuwano, R., Iwatsubo, T., Matsuda, H., (ADNI), F. T. J. A. D. N. I., & (J-ADNI), T. J. A. D. N. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160621 · Cited by 40
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 40
Sun, X., Yu, X., Zhu, J., Li, L.-J., Zhang, L., Huang, Y., Liu, D., Ji, M., Sun, X., Zhang, L. L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01273-8 · Cited by 42
Lawrence, V. C., Pickett, J., Ballard, C. G., & Murray, J. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3958 · Cited by 39
Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
St‐Amour, I., Cicchetti, F., & Calon, F. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1518-9 · Cited by 40
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
Portelius, E., Mattsson, N., Pannee, J., Zetterberg, H., Gisslén, M., Vanderstichele, H., Gkanatsiou, E., Crespi, G. A. N., Parker, M. W., Miles, L. A., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0152-5 · Cited by 39
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
Brashear, H. R., Ketter, N., Bogert, J., Di, J., Salloway, S., & Sperling, R. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180675 · Cited by 39
Self-citationApoE mimetic improves pathology and memory in a model of Alzheimer’s disease
Krishnamurthy, K., Cantillana, V., Wang, H., Sullivan, P. M., Kolls, B. J., Ge, X., Lin, Y., Mace, B., & Laskowitz, D. T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146685 · Cited by 39
Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases
Schwarz, C. G. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01030-9 · Cited by 40
Agger, M. P., Danielsen, E. R., Carstensen, M. S., Nguyen, N. M., Horning, M., Henney, M. A., Jensen, C. B. R., Baandrup, A. O., Kjær, T. W., Madsen, K. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221238 · Cited by 40
Inflammatory Cerebral Amyloid Angiopathy: A Broad Clinical Spectrum
de Souza, A., & Tasker, K. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0493 · Cited by 38
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 39
Metadata
- Authors
- Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Lieberburg, I., Arrighi, H. M., Morris, K. A., Lu, Y., Liu, E., Gregg, K. M., Brashear, H. R., Kinney, G. G., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Butler Hospital (US)
- Imperial College London (GB)
- McGill University (CA)
- California Pacific Medical Center (US)
- UCL Queen Square Institute of Neurology (GB)
- Columbia University (US)
- University of Rochester Medicine (US)
- University of California, San Francisco (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Sperling, Reisa
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 241-249
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4063417
- OpenAlex
- W2122843800
- Cited by
- 512
- References
- 27
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 51 · 2023: 35 · 2022: 47 · 2021: 32 · 2020: 31 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 29 · 2015: 47 · 2014: 36 · 2013: 39 · 2012: 17
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10123)
- Elan
- National Institute on Aging (K24AG035007, P50AG005134, P30AG062421)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- amyloid-related imaging abnormalities, bapineuzumab, Alzheimer's disease, amyloid-beta, ARIA-E, ARIA-H, vasogenic edema, microhemorrhages, APOE ε4, dose-dependent risk, risk factors, FLAIR MRI, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Retrospective Studies, Risk Factors, Amyloid beta-Peptides, Neuroimaging, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
